EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and …
T Takano, T Fukui, Y Ohe, K Tsuta… - Journal of Clinical …, 2008 - ascopubs.org
Purpose This study evaluated whether the presence of epidermal growth factor receptor
(EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic …
(EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic …
Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations
P Van Luan, ND Tien, NM Hai… - … Advances in Medical …, 2021 - journals.sagepub.com
Background: There have been few studies on the efficacy of tyrosine kinase inhibitors in
lung carcinomas. The purpose of this study was to evaluate the effect of gefitinib as a first …
lung carcinomas. The purpose of this study was to evaluate the effect of gefitinib as a first …
[引用][C] Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction
PA Jänne - Journal of Clinical Oncology, 2006 - ascopubs.org
In the spring of 2004, the association between somatic mutations in the epidermal growth
factor receptor (EGFR) in non–small-cell lung cancer (NSCLC) and sensitivity to the EGFR …
factor receptor (EGFR) in non–small-cell lung cancer (NSCLC) and sensitivity to the EGFR …
[HTML][HTML] Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression …
Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive …
N Yoshimura, S Kudoh, S Mitsuoka, N Yoshimoto… - Lung cancer, 2015 - Elsevier
Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …
[HTML][HTML] Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase …
Y Taniguchi, A Tamiya, K Nakahama… - Oncology …, 2017 - spandidos-publications.com
The aim of the present study was to analyze the impact of metastatic status on the prognosis
of epithelial growth factor receptor (EGFR) mutation‑positive patients with non‑small cell …
of epithelial growth factor receptor (EGFR) mutation‑positive patients with non‑small cell …
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
Gefitinib is effective in treating advanced non-small cell lung cancer (NSCLC), especially in
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …
[HTML][HTML] A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III non–small-cell lung cancer harboring EGFR mutations …
H Akamatsu, H Harada, S Tokunaga, N Yoshimura… - Clinical lung cancer, 2019 - Elsevier
Locally advanced non–small-cell lung cancer (NSCLC) is curable. Standard treatment is
concurrent chemoradiotherapy, but its efficacy with cytotoxic agents seems to reach a …
concurrent chemoradiotherapy, but its efficacy with cytotoxic agents seems to reach a …
[HTML][HTML] Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non–small cell lung cancer: epidermal growth factor receptor mutations …
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been
introduced in the standard therapy of non–small-cell lung cancer (NSCLC), but they benefit …
introduced in the standard therapy of non–small-cell lung cancer (NSCLC), but they benefit …
Disease flare after gef itinib discontinuation
H Akamatsu, A Ono, T Shukuya, A Tsuya… - Respiratory …, 2015 - Elsevier
Introduction A recent retrospective analysis found that 23% of non-small cell lung cancer
patients who acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine …
patients who acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine …